ClinicalTrials.gg
RecruitingNCT06486779CHRONOSUpdated Jun 11, 2026

Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study

An observational study in Relapsing Multiple Sclerosis (RMS), sponsored by Novartis Pharmaceuticals. Recruiting at 15 sites in Greece. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
160
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Multiple Sclerosis by Novartis — 9 open to participants now, 23 under way, 6 of them phase 3. Multiple Sclerosis · Novartis.

Planned enrollment
29th of 41
160 · median 312
Started
2024
with 8 others
Observational
41 of 106
7 open now
Primary completion
2028-12
later than 15 of 22 live
Registered
90th of 106
by date

Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 29th largest by planned enrollment of the 41 observational ones that give a count, is one of 9 that started in 2024, is one of 41 observational ones, reaches primary completion later than 15 of the 22 other live ones, and was the 90th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

9 of the 106 studies in Multiple Sclerosis by Novartis are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Multiple Sclerosis by Novartis, or all of them as a file.
02

Study summary

This study is a single-country, non-interventional, multicenter, observational study, mainly based on primary data collection to assess the effect of ofatumumab on clinical parameters of Multiple Sclerosis (MS) in a routine medical care setting, as compared to the standard of care (SoC) arm of a closely monitored phase-IIIb study (STHENOS, which includes glatiramer acetate, interferons, teriflunomide, or dimethyl fumarate)

Read the detailed description

Primary data from MS adult patients who initiate ofatumumab early in their disease course will be collected over a period of two years, and will be compared to the ofatumumab and Standard of Care (SoC) arms of the STHENOS trial, a closely monitored phase-IIIb trial. Eligible patients are those with Relapsing Multiple Sclerosis (RMS) diagnosis, with 1st MS symptom within 5 years prior to ofatumumab's initiation and on treatment with ofatumumab for at least 3 months, but not longer than 6 months prior to inclusion in the study. The overall study duration is expected to be 48 months, including a recruitment period and a per-patient observation period of 24 months each. Follow-up visit frequency will be determined by the treating physician, however study-related data will be collected at study enrollment and at 6-, 12-, 18-, and 24-month data collection timepoints post with an allowable time window of ±1 month for all data collection timepoints. NEDA-3 status, MS Relapse, EDSS, MRI, PROs questionnaires, MSIS-29, SDMT, Adherence and persistence, AEs will be assessed during the study.

03

Conditions studied

  • Relapsing Multiple Sclerosis (RMS)

Browse trials for

Keywords

  • Relapsing Multiple Sclerosis (RMS)
  • RMS
  • NIS
  • Greece
  • Ofatumumab
  • Kesimpta
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with RMS who have initiated treatment with ofatumumab early in their disease course. Patients will have been administered ofatumumab (Kesimpta®) three to six months prior to informed consent (IC) and will continue to be treated according to the local product's prescribing information and routine medical practice in terms of visit frequency and type of assessments performed, after enrolment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written IC must be obtained before participating in the study.
  2. Patients with diagnosis of RMS per McDonald Criteria (2017) and \<5 years since first MS symptom prior to initiation of ofatumumab.
  3. Patients who have been on treatment with ofatumumab for at least 3 months, but not longer than 6 months prior to inclusion in the study.
  4. Ofatumumab treatment in line with the European Product Information of Kesimpta (i.e., adult patients with relapsing forms of MS with active disease defined by clinical or imaging features).
  5. Patients with at least one available brain MRI scan performed at least 3 months after ofatumumab initiation OR for whom the physician (as per her/his routine practice and independently of his/her decision to include the patient in the current study) plans to perform such scanning within 31 days after patient's inclusion in the study.

    Notes: This MRI scan can be either brain gadolinium enhanced (Gd+) or not. In case it is not gadolinium enhanced, the most recent MRI prior to ofatumumab treatment should be brain gadolinium enhanced, for relevant comparison and identification of new lesions. This MRI scan will serve as the index reference assessment for the evaluation of NEDA-3 radiological component and shall not have been performed within 30 days after the termination of therapy.

  6. Patients willing and able to complete the assessments, including PRO questionnaires, as per physicians' clinical practice and as outlined in this study.

Exclusion criteria

Exclusion Criteria:

  1. Use of drugs during the study, OR between ofatumumab initiation and inclusion into the study, OR within 3 months before ofatumumab initiation, OR within 5 half-lives of investigational drug before ofatumumab initiation, OR until the expected pharmacodynamic effect has returned to baseline, whichever is longer.
  2. Currently pregnant (or intention to become pregnant within the study period), breastfeeding or lactating women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No

Groups and cohorts

  • CHRONOS cohort

    Patients prescribed with ofatumumab in a real world setting

    Other: Ofatumumab

Interventions

  • OtherOfatumumab

    This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.

06

What researchers measure

Primary outcomes

  1. Proportion of patients with no evidence of disease activity (NEDA-3) compared to SoC arm of STHENOS

    Achievement of NEDA-3 status (no evidence of disease activity based on three components): A) No confirmed multiple sclerosis clinical relapse B) No new MRI brain activity (no new or enlarging T2 lesions, no gadolinium positive (Gd+) T1 lesions) C) No six-month confirmed disability worsening (6m-CDW).

    Time frame: 12 months post-enrollment for Chronos cohort and 15 months post-baseline for SoC arm of Sthenos

Secondary outcomes

  1. Proportion of patients achieving NEDA-3 status compared to Ofatumumab arm of STHENOS

    Achievement of NEDA-3 status (no evidence of disease activity based on three components): A) No confirmed multiple sclerosis clinical relapse B) No new MRI brain activity (no new or enlarging T2 lesions, no gadolinium positive (Gd+) T1 lesions) C) No six-month confirmed disability worsening (6m-CDW).

    Time frame: 12 months post-enrollment for Chronos cohort and 15 months post-baseline for ofatumumab arm of Sthenos

  2. Proportion of patients achieving each individual component of NEDA-3 compared to Ofatumumab arm of STHENOS

    Achievement of NEDA-3 status and individual NEDA-3 components: A) Proportion of patients with no confirmed multiple sclerosis clinical relapse B) Proportion of patients with no new or enlarging T2 lesions, no gadolinium positive (Gd+) T1 lesions C) Proportion of patients with no six-month confirmed disability worsening (6m-CDW).

    Time frame: 12 months post-enrollment for Chronos cohort and 15 months post-baseline for ofatumumab arm of Sthenos

  3. Proportion of patients achieving NEDA-3 status (no comparator)

    Achievement of NEDA-3 status (no evidence of disease activity based on three components): A) No confirmed multiple sclerosis clinical relapse B) No new MRI brain activity (no new or enlarging T2 lesions, no gadolinium positive (Gd+) T1 lesions) C) No six-month confirmed disability worsening (6m-CDW).

    Time frame: 18 months post-enrollment

  4. Proportion of patients achieving each individual component of NEDA-3 (no comparator)

    Achievement of NEDA-3 status and individual NEDA-3 components: A) Proportion of patients with no confirmed multiple sclerosis clinical relapse B) Proportion of patients with no new or enlarging T2 lesions, no gadolinium positive (Gd+) T1 lesions C) Proportion of patients with no six-month confirmed disability worsening (6m-CDW).

    Time frame: 18 months post-enrollment

  5. Proportion of patients free of 6m-RAW and 6m-PIRA - no comparator

    * Proportion of patients free of 6-month confirmed relapse-associated worsening (6m-RAW) * Proportion of patients free of 6-month confirmed progression independent of relapse activity (6m-PIRA) * Proportion of patients free of both 6m-RAW and 6m-PIRA

    Time frame: 12 and 18 months post-enrollment

  6. Change in MSIS-29 impact score from enrollment.

    * Change in MSIS-29 physical impact score from enrollment. * Change in MSIS-29 psychological impact score from enrollment. The MSIS-29 is a brief self-reported measurement of the impact of multiple sclerosis on patients' quality of life (measuring 20 items for physical \& 9 items for mental/psychological health), where high scores indicate worse health.

    Time frame: Enrollment, 12, 18 and 24 months post-enrollment

  7. Persistence and treatment discontinuation

    Proportion of patients remaining on treatment with ofatumumab and proportion of patients permanently discontinuing ofatumumab during the study.

    Time frame: 24 months post-enrollment

  8. Time from the start of ofatumumab to all-cause treatment discontinuation

    Time from the start of ofatumumab to all-cause treatment discontinuation

    Time frame: 24 months post-enrollment

07

Study locations

14 of 15 sites recruiting
  • Novartis Investigative Site
    Athens, Attica 15562, Greece
    Recruiting
  • Novartis Investigative Site
    Athens, GR 115 26, Greece
    Recruiting
  • Novartis Investigative Site
    Alexandroupoli, 681 00, Greece
    Recruiting
  • Novartis Investigative Site
    Athens, 115 21, Greece
    Recruiting
  • Novartis Investigative Site
    Athens, 115 25, Greece
    Recruiting
  • Novartis Investigative Site
    Athens, 115 27, Greece
    Recruiting
  • Novartis Investigative Site
    Athens, 115 28, Greece
    Withdrawn

    Not enrolling at this site.

  • Novartis Investigative Site
    Athens, 145 61, Greece
    Recruiting
  • Novartis Investigative Site
    Chaïdári, 124 62, Greece
    Recruiting
  • Novartis Investigative Site
    Crete Heraklion, 714 09, Greece
    Recruiting
  • Novartis Investigative Site
    Ioannina, 455 00, Greece
    Recruiting
  • Novartis Investigative Site
    Larissa, 411 10, Greece
    Recruiting
  • Novartis Investigative Site
    Pátrai, 265 04, Greece
    Recruiting
  • Novartis Investigative Site
    Thessaloniki, 53246, Greece
    Recruiting
  • Novartis Investigative Site
    Thessaloniki, 54636, Greece
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2028, 48 months after the start.

Of 91 industry-sponsored observational studies under Multiple Sclerosis, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 75. This study's planned 48 months is close to that.

Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2024
First posted
Jul 5, 2024
StartActual
Dec 10, 2024
Primary completionEst.
Dec 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06486779
Responsible party
Sponsor
First posted
Jul 5, 2024
Start date
Dec 10, 2024
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Jun 11, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion